These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19. Li K; Meyerholz DK; Bartlett JA; McCray PB mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553 [TBL] [Abstract][Full Text] [Related]
31. ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery. Lores E; Wysocki J; Batlle D Clin Sci (Lond); 2020 Nov; 134(21):2791-2805. PubMed ID: 33135725 [TBL] [Abstract][Full Text] [Related]
32. ACE2 and TMPRSS2 immunolocalization and oral manifestations of COVID-19. Park GC; Bang SY; Lee HW; Choi KU; Kim JM; Shin SC; Cheon YI; Sung ES; Lee M; Lee JC; Kim HS; Lee BJ Oral Dis; 2022 Nov; 28 Suppl 2():2456-2464. PubMed ID: 35000261 [TBL] [Abstract][Full Text] [Related]
33. Going viral in the islet: mediators of SARS-CoV-2 entry beyond ACE2. Rangu R; Wander PL; Barrow BM; Zraika S J Mol Endocrinol; 2022 Jun; 69(2):R63-R79. PubMed ID: 35521990 [TBL] [Abstract][Full Text] [Related]
34. Impact of ACE2 on the susceptibility and vulnerability to COVID-19. Pringle KG; Philp LK J Endocrinol; 2023 Sep; 258(3):. PubMed ID: 37439513 [TBL] [Abstract][Full Text] [Related]
35. Androgens, the kidney, and COVID-19: an opportunity for translational research. Yanes Cardozo LL; Rezq S; Pruett JE; Romero DG Am J Physiol Renal Physiol; 2021 Feb; 320(2):F243-F248. PubMed ID: 33464168 [TBL] [Abstract][Full Text] [Related]
36. Repeated ethanol exposure and withdrawal alters angiotensin-converting enzyme 2 expression in discrete brain regions: Implications for SARS-CoV-2 neuroinvasion. Balasubramanian N; James TD; Selvakumar GP; Reinhardt J; Marcinkiewcz CA Alcohol Clin Exp Res (Hoboken); 2023 Feb; 47(2):219-239. PubMed ID: 36529893 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies. Ragia G; Manolopoulos VG Eur J Clin Pharmacol; 2020 Dec; 76(12):1623-1630. PubMed ID: 32696234 [TBL] [Abstract][Full Text] [Related]
39. Study on the potential of Sanghuangporus sanghuang and its components as COVID-19 spike protein receptor binding domain inhibitors. Chien LH; Deng JS; Jiang WP; Chen CC; Chou YN; Lin JG; Huang GJ Biomed Pharmacother; 2022 Sep; 153():113434. PubMed ID: 36076488 [TBL] [Abstract][Full Text] [Related]
40. The contrasting role of nasopharyngeal angiotensin converting enzyme 2 (ACE2) transcription in SARS-CoV-2 infection: A cross-sectional study of people tested for COVID-19 in British Columbia, Canada. Nikiforuk AM; Kuchinski KS; Twa DDW; Lukac CD; Sbihi H; Basham CA; Steidl C; Prystajecky NA; Jassem AN; Krajden M; Patrick DM; Sekirov I EBioMedicine; 2021 Apr; 66():103316. PubMed ID: 33819740 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]